DOCSLIB.ORG

(104B) Sponsored by Merrill Corporation Celtics Room

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

As of June 18, 2012 Schedule subject to change Monday, Patriots Room (104B) Red Sox Room (104A) Celtics Room (104C) Bruins Room (105) June 18 Sponsored by Merrill Corporation Myelin Repair Foundation Eleven Biotherapeutics Altherx Immunovaccine, Inc. 1:00 PM Patient Advocacy Group Ophthalmology Gastroenterology, Urological Oncology, Infectious Diseases Janssen Pharmaceutical Companies of Advaxis, Incorporated BL Pharmaceuticals AIMM Therapeutics BV 1:15 PM Johnson & Johnson Leading Biotech/Big Pharma Oncology Biopharmaceuticals Biopharmaceuticals Biogen Idec, Inc. Critical Outcome Technologies Inc. Latona Life Sciences, Inc. Zymeworks Inc. 1:30 PM Leading Biotech/Big Pharma Oncology Autoimmune/Inflammation Biopharmaceuticals Shire plc Progenics Pharmaceuticals, Inc. Affinium Pharmaceuticals Onconova Therapeutics Incorporated 1:45 PM Leading Biotech/Big Pharma Oncology Infectious Diseases Biopharmaceuticals MERCK ALS Therapy Development Institute AdeTherapeutics Inc. Aduro BioTech, Inc. 2:00 PM Leading Biotech/Big Pharma Patient Advocacy Group Autoimmune/Inflammation Oncology Amgen, Inc. Synergenics, LLC CytomX Therapeutics, Inc. Aptalis Pharma 2:15 PM Leading Biotech/Big Pharma Biopharmaceuticals Platform Technologies GI Disorders/Drug Delivery/Technologies CD Diagnostics, Inc. TBD Rhythm Savant HWP, Inc. 2:30 PM Diagnostics Metabolic Diseases CNS GlaxoSmithKline TBD Verastem ImmusanT, Inc. 2:45 PM Leading Biotech/Big Pharma Oncology Autoimmune/Inflammation United States Army Medical Research & Office of Translational Research, Ntl Institute of BioMarin Pharmaceutical Inc. CoMentis, Inc. 3:00 PM Materiel Command Neuro. Disorders & Stroke Leading Biotech/Big Pharma CNS Drug Development CNS Abbott TBD TBD TBD 3:15 PM Leading Biotech/Big Pharma AstraZeneca TBD TBD Hepregen Corporation 3:30 PM Leading Biotech/Big Pharma Platform Technologies MedImmune Aphios Corporation Organogenesis, Inc. Syndexa Pharmaceuticals Corp. 3:45 PM Leading Biotech/Big Pharma Oncology, Infectious Diseases Regenerative Medicine Metabolic Diseases Presentations are open to all Convention attendees and are located on Level 1 As of June 18, 2012 - Schedule subject to change Tuesday, Red Sox Room (104A) Patriots Room (104B) Celtics Room (104C) Bruins Room (105) June 19 Roche 8:00 AM Leading Biotech/Big Pharma Genentech Alexion Pharmaceuticals Advanced Cell Technology 8:15 AM Leading Biotech/Big Pharma Leading Biotech/Big Pharma Regenerative Medicine Takeda Pharmaceutical Company Aurigene Discovery Technologies Ltd Antisense Pharma Anteo Diagnostics 8:30 AM Leading Biotech/Big Pharma Oncology Oncology Diagnostics Ironwood Pharmaceuticals, Inc. Spectra Analysis Instruments Inc. PDS Biotechnology Corporation Applied Biotechnology Institute, Inc. 8:45 AM Metabolic Diseases Tools Oncology, Infectious Diseases Platform Technologies Upsher-Smith Laboratories, Inc. Delphi Genetics SA OncoSec Medical, Inc. Kibow Biotech Inc 9:00 AM Leading Biotech/Big Pharma Platform Technologies Oncology Renal, Metabolic Diseases Pfizer, Inc Mannkind Corporation NeoStem, Inc. Cumberland Emerging Technologies, Inc. 9:15 AM Leading Biotech/Big Pharma Novel Drug Delivery Cardiovascular, Autoimmune Drug Development Luminex Corporation Betagenon AB ADVENTRX Pharmaceuticals, Inc. P2D Bioscience 9:30 AM Diagnostics Metabolic Diseases Oncology, Infectious Diseases CNS Immunocellular Therapeutics, Ltd Ultragenyx Pharmaceutical Immunomic Therapeutics, Inc. Dicerna Pharmaceuticals 9:45 AM Oncology Genetic Diseases Oncology, Autoimmune/Inflammation Infectious Diseases Eli Lilly and Company AgonOX Senesco Technologies Ikaria, Inc. 10:00 AM Leading Biotech/Big Pharma Oncology Oncology, Autoimmune/Inflammation Respiratory, Critical Care Bayer HealthCare Deuteria Pharmaceuticals, Inc. MorphoSys AG Michael J. Fox Foundation 10:15 AM Leading Biotech/Big Pharma Buzz of BIO Winner - Oncology Oncology, Autoimmune/Inflammation Patient Advocacy Group Human Genome Sciences MaxCyte, Inc. Zalicus Inc. Endoceutics Inc 10:30 AM Leading Biotech/Big Pharma Platform Technologies CNS Oncology Biotie Therapies Corp. Syndax Pharmaceuticals, Inc. Viralytics Ltd InVasc Therapeutics, Inc. 10:45 AM CNS Oncology Oncology Renal, Cardiovascular TBD Aurinia Pharmaceuticals Cytokinetics, Inc. Histogen 2:00 PM Autoimmune/Inflammation Musculoskeletal Regenerative Medicine Sanofi Vitae Pharmaceuticals, Inc. Resverlogix Corp. VLST Corp 2:15 PM Leading Biotech/Big Pharma Oncology CNS Autoimmune/Inflammation Genzyme Corporation BiondVax Pharmaceuticals Ltd Endotis Pharma TBD 2:30 PM Leading Biotech/Big Pharma Vaccines Cardiovascular Sanofi Pasteur WuXi AppTec, Inc Bionomics Ltd H. Lundbeck A/S 2:45 PM Leading Biotech/Big Pharma Drug Development Oncology, Drug Discovery CNS DAIICHI SANKYO Immune Design Heptares Therapeutics Limited TSRL, Inc. 3:00 PM Leading Biotech/Big Pharma Vaccines CNS/Metabolic Diseases Drug Delivery Glycotope GmbH Debiopharm SA PolyMedix,. Inc. HungaroTrial 3:15 PM Oncology Oncology, Autoimmune/Inflammation Infectious Diseases CRO/CMO EMD Serono Kalos Therapeutics, Inc. Pharmaneuroboost NV Karyopharm Therapeutics, Inc. 3:30 PM Leading Biotech/Big Pharma Oncology CNS Oncology, Autoimmune/Inflammation Protalix LTD Allinky Biopharma Synergy Pharmaceuticals INC. Genocea Biosciences, Inc. 3:45 PM Genetic Diseases Oncology, CNS Gastrointestinal Disorders Infectious Diseases Presentations are open to all Convention attendees and are located on Level 1 As of June 18, 2012 - Schedule subject to change Wed, Red Sox Room (104A) Patriots Room (104B) Celtics Room (104C) Bruins Room (105) June 20 Boehringer Ingelheim ZARZATECH INC Genta Incorporated Kancera AB 8:30 AM Leading Biotech/Big Pharma Oral Health Oncology Oncology Office of Clinical Research, Ntl Institute of Neuro. Immunocore Limited Ganymed Pharmaceuticals AG Hybrigenics 8:45 AM Disorders & Stroke Oncology CNS Oncology Oncology Ipsen Pharma The Wellcome Trust GENFIT CORP. Arch Pharmalabs Ltd. 9:00 AM Biopharmaceuticals Funding/Partnering Cardiovascular Drug Development Curis, Inc. Xcellerex Inc. AGC Biotechnology Ezose Sciences Inc. 9:15 AM Oncology Infectious Diseases Leading Biotech/Big Pharma Drug Development/Platform Technologies Novozymes sterna biologicals GmbH & Co. KG Galena Biopharma, Inc. Constellation Pharmaceuticals 9:30 AM Leading Biotech/Big Pharma Respiratory, Dermatological Drug Delivery Oncology PurGenesis Agile Therapeutics SK Biopharmaceuticals TBD 9:45 AM Gastrointestinal Disorders, Dermatology Reproductive Medicine Biopharmaceuticals MolMed S.p.A. Hematech, Inc. TBD Exemplar Genetics 10:00 AM Oncology Biopharmaceuticals Drug Development Univ. of Pittsburgh, Office of Technology EpiCept Corporation Enzon Pharmaceuticals Bavarian Nordic A/S 10:15 AM Management Oncology Oncology Infectious Diseases Tech Transfer Apricus Biosciences, Inc. Bigtec Labs, Bigtec Private Limited Idera Pharmaceuticals, Inc. Atlas Antibodies AB 10:30 AM CNS, Oncology Diagnostics Oncology Platform Technologies BioSante Pharmaceuticals, Inc. Nanobiotix Biomay AG Metabolon, Inc. 10:45 AM Reproductive Medicine Oncology Autoimmune/Inflammation Diagnostics Colby Pharmaceutical Company MDA Venture Philanthropy Proximagen Group plc SAGETIS BIOTECH, SL 2:00 PM Biopharmaceuticals Patient Advocacy Group CNS CNS Karolinska Development AB Orbis Biosciences, Inc. Allegro Diagnostics Grünenthal GmbH 2:15 PM Oncology, Cardiovascular Drug Delivery Diagnostics CNS Sandoz GmbH, Austria (a Novartis Hemispherx Biopharma, Inc. Isu Abxis KLOX Technologies inc. 2:30 PM company) CNS, Infectious Diseases Oncology, Autoimmune/Inflammation Biopharmaceuticals Medical Devices PAION AG Ziopharm Oncology, Inc. Dyax Corp Rheonix, Inc. 2:45 PM Cardiovascular, CNS Oncology Oncology, Autoimmune/Inflammation Platform Technologies TBD Faulk Pharmaceuticals Inc. MGB Biopharma Limited Aileron Therapeutics 3:00 PM Oncology, Drug Delivery Infectious Diseases Drug Delivery oncimmune LLC Oryzon Genomics, S.A. Bionor Pharma ASA Samsung BioLogics Ltd. 3:15 PM Oncology Oncology Vaccines Drug Development Ohr Pharmaceutical Inc. Hermo Pharma Ltd. LipoPharma Therapeutics SL 3P Biopharmaceuticals 3:30 PM Oncology CNS CNS CMO/CRO Dara BioSciences, Inc. Aura Biosciences, Inc. 3:45 PM Oncology Oncology Presentations are open to all Convention attendees and are located on Level 1 Thank you to our Company Presenters! Interested in presenting at other events? Email Sondra at [email protected].
Recommended publications
  • BIOWORLD TODAY Inquiry

    BIOWORLD TODAY Inquiry

    BIOWORLDTM TODAY THE DAILY BIOPHARMACEUTICAL NEWS SOURCE JUNE 30 , 2016 BIOTECH’S MOST RESPECTED NEWS SOURCE FOR MORE THAN 20 YEARS VOLUME 27, NO. 126 LIPID JAM NOT OVER EASILY STOPPED FOR FUTILITY Waffle house? FDA Galena Biopharma implodes as PRESENT review fidgets endpoint, puts cancer vaccine Neuvax future in doubt outcome details; By Jennifer Boggs, Managing Editor Esperion grilled on holdup With the bulk of Galena Biopharma Inc.’s value riding on cancer vaccine Neuvax By Randy Osborne, Staff Writer (nelipepimut-S), the firm’s shares predictably plunged to a new 52-week low Wednesday as an independent data monitoring committee (IDMC) recommended the Analysts had plenty of questions but PRESENT phase III study in breast cancer be stopped for futility following a planned Esperion Therapeutics Inc. offered few interim analysis. But it’s the troubling language in the IDMC’s letter, suggesting the answers regarding the FDA’s stalling on placebo arm might actually have bested the treatment arm, that could signal the end oral, once-daily bempedoic acid (ETC- of the road for Neuvax. 1002) for lipid lowering, after the agency See Galena, page 3 See Esperion, page 4 CHINA DEALS AND M&A IN THE CLINIC Pfizer invests in Asia Merck strikes cancer SUPER ‘NOVA’ with $350M biotech vaccines deal with Tesaro shares blast plant in Hangzhou Moderna, delivering off as niraparib hits By Haky Moon, Staff Writer $200M up front PFS in ovarian cancer HONG KONG – China’s economy may By Michael Fitzhugh, Staff Writer By Marie Powers, News Editor be slowing down, but multinationals Findings from the phase III NOVA trial are positioning themselves to leverage Cancer vaccines tailored to fit tumor- specific profiles are at the heart of a new of niraparib in women with recurrent it as best they can while navigating a ovarian cancer blasted shares of still-complex regulatory environment.
  • BIO-2005-MK-ONLINE (Page 1)

    BIO-2005-MK-ONLINE (Page 1)

    THE SCIENCE. THE BUSINESS. THE WORLD OF BIOPHARMACEUTICALS. 2005 MEDIA PLANNER www.biopharminternational.com THE PRINT-BASED MARKETING Display Advertising BIOPHARM The foundation of any b-to-b marketing program, print advertising allows you to BRAND touch 29,200 BPA-qualified subscribers* with your brand or product message. BioPharm International’s Build your marketing plan around the message portfolio of products allows conveyed in your print ad and utilize other channels you to reach our highly to further reinforce your message. desirable audience through multiple marketing channels. Custom Publishing Work with us to write and design a custom white paper or article Studies show integrated published as an advertorial in the pages of BioPharm. marketing is the key to successfully delivering your Insert A unique way to deliver white papers, brochures or any other collateral message to today’s buyer. material to our readers. Reinforce your message to the most important audience Polybag in your market—ask your Talk about premium placement! Send your printed piece as a ride-along advertising sales manager and readers will get the message as soon as the issue hits their desk. to design an integrated program Direct Mail utilizing the channels that best Planning a direct mail campaign to reinforce your ad message? meet your marketing objectives. Rent our list to ensure your marketing material reaches your most important audience. Post-It Note A truly unique way to send your message to our readers, Post-It Notes serve as front cover reminders about your brand. Use Post-Its to call out your ads in the issue or run 6 or 12 Post-It Notes for a truly unique campaign.
  • Breaking Eroom's

    Breaking Eroom's

    Breaking Eroom’s Law Michael S. Ringel, Jack W. Scannell, Mathias Baedeker and Ulrik Schulze https://doi.org/10.1038/d41573-020-00059-3 Supplementary Box 1 | Data and analysis Breaking Eroom’s Law The count and value of NMEs relative to R&D spend comes from BCG’s New Therapeutic Drug (NTD) Database, which is also the source of BCG’s annual publication in Nat. Rev. Drug. Discov. showing trends in count and value over time.1 FDA approvals are from FDA’s Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER),2 peak sales estimates are from EvaluatePharma®,3 and R&D spend data are from BCG Value Science, inflation-adjusted using the standard global GDP-based inflator from the Economist Intelligence Unit.4 For additional details on methodology, see Schulze, Baedeker, Chen and Greber.5 Eroom’s Law is linear on a log scale through 2010, with an average increase approximately 12% per annum, or a halving of productivity approximately every seven years. If this holds true even after 2010, we would see a continuation of the linear development of the number of drugs approved per billion US$ R&D spending when using a logarithmic scale. To demonstrate that the deviation from regression after 2010 is statistically relevant we assumed the following: 1) Eroom's law is true up to 2010. 2) Eroom's law is not true between 2010 and 2018. To confirm our assumptions, we used a log-linear regression to describe the number of new molecular entities (NMEs) approved by the US FDA per billion US$ R&D spending from 1950–2010.
  • List of Section 13F Securities

    List of Section 13F Securities

    List of Section 13F Securities 1st Quarter FY 2004 Copyright (c) 2004 American Bankers Association. CUSIP Numbers and descriptions are used with permission by Standard & Poors CUSIP Service Bureau, a division of The McGraw-Hill Companies, Inc. All rights reserved. No redistribution without permission from Standard & Poors CUSIP Service Bureau. Standard & Poors CUSIP Service Bureau does not guarantee the accuracy or completeness of the CUSIP Numbers and standard descriptions included herein and neither the American Bankers Association nor Standard & Poor's CUSIP Service Bureau shall be responsible for any errors, omissions or damages arising out of the use of such information. U.S. Securities and Exchange Commission OFFICIAL LIST OF SECTION 13(f) SECURITIES USER INFORMATION SHEET General This list of “Section 13(f) securities” as defined by Rule 13f-1(c) [17 CFR 240.13f-1(c)] is made available to the public pursuant to Section13 (f) (3) of the Securities Exchange Act of 1934 [15 USC 78m(f) (3)]. It is made available for use in the preparation of reports filed with the Securities and Exhange Commission pursuant to Rule 13f-1 [17 CFR 240.13f-1] under Section 13(f) of the Securities Exchange Act of 1934. An updated list is published on a quarterly basis. This list is current as of March 15, 2004, and may be relied on by institutional investment managers filing Form 13F reports for the calendar quarter ending March 31, 2004. Institutional investment managers should report holdings--number of shares and fair market value--as of the last day of the calendar quarter as required by Section 13(f)(1) and Rule 13f-1 thereunder.
  • Monday, April 22 Chicago Bears Room Chicago Bulls Room Chicago Cubs Room Merck KLOX Technologies Immune Design Leading Biote

    Monday, April 22 Chicago Bears Room Chicago Bulls Room Chicago Cubs Room Merck KLOX Technologies Immune Design Leading Biote

    As of 4/23/2013 Schedule subject to change Monday, Chicago Bears Room Chicago Bulls Room Chicago Cubs Room April 22 Merck KLOX Technologies Immune Design 1:00 PM Leading Biotech/Big Pharma Medical Devices Vaccines Eli Lilly NewSouth Innovations Syntiron 1:15 PM Leading Biotech/Big Pharma University/Academia Vaccines Amgen Radius Health BioCrea 1:30 PM Leading Biotech/Big Pharma Musculoskeletal Neurology/CNS Nat. Inst. of Neurological Dis. & Stroke Cytokinetics Xenon Pharmaceuticals 1:45 PM Neurology/CNS Musculoskeletal Neurology/CNS Curis OrgaNext Research BV Trigemina 2:00 PM Oncology Regenerative Medicine Neurology/CNS Verastem Flexion Therapeutics Neurocrine Biosciences 2:15 PM Oncology Musculoskeletal Hormone Therapy/CNS Michael J. Fox Foundation Antisense Pharma GmbH Versartis 2:30 PM Non-profit/Patient Advocacy Oncology Hormone Therapy Takeda Pharmaceutical Company TBD KODE Biotech 2:45 PM Leading Biotech/Big Pharma Drug Delivery Resverlogix Corp. Advaxis Q Chip 3:00 PM Cardiovascular Disease Oncology Drug Delivery Grünenthal GmbH Array BioPharma 3:15 PM Neurology/CNS Oncology/Drug Discovery Discovery Labs Mersana Therapeutics 3:30 PM Drug Delivery/Pulmonary Oncology Bayer HealthCare Igenica 3:45 PM Leading Biotech/Big Pharma Oncology Presentations are open to all Convention attendees and are located outside the main entrance of the BIO Business Forum As of 4/23/2013 - Schedule subject to change Tuesday, Chicago Bears Room Chicago Bulls Room Chicago Cubs Room Chicago Blackhawks Room April 23 Pfizer 8:00 AM Leading Biotech/Big Pharma
  • Medicaid System (Mmis) Illinois Department of Run Date: 08/08/2015 Provider Subsystem Healthcare and Family Services Run Time: 21:25:58 Report Id 2794D052 Page: 01

    Medicaid System (Mmis) Illinois Department of Run Date: 08/08/2015 Provider Subsystem Healthcare and Family Services Run Time: 21:25:58 Report Id 2794D052 Page: 01

    MEDICAID SYSTEM (MMIS) ILLINOIS DEPARTMENT OF RUN DATE: 08/08/2015 PROVIDER SUBSYSTEM HEALTHCARE AND FAMILY SERVICES RUN TIME: 21:25:58 REPORT ID 2794D052 PAGE: 01 ALPHA COMPLETE LIST OF PHARMACEUTICAL LABELERS WITH SIGNED REBATE AGREEMENTS IN EFFECT AS OF 10/01/2015 NDC NDC PREFIX LABELER NAME PREFIX LABELER NAME 68782 (OSI) EYETECH 65162 AMNEAL PHARMACEUTICALS LLC 00074 ABBOTT LABORATORIES 69238 AMNEAL PHARMACEUTICALS, LLC 68817 ABRAXIS BIOSCIENCE, LLC 53150 AMNEAL-AGILA, LLC 16729 ACCORD HEALTHCARE INCORPORATED 00548 AMPHASTAR PHARMACEUTICALS, INC. 42192 ACELLA PHARMACEUTICALS, LLC 66780 AMYLIN PHARMACEUTICALS, INC. 10144 ACORDA THERAPEUTICS, INC. 55724 ANACOR PHARMACEUTICALS 00472 ACTAVIS 10370 ANCHEN PHARMACEUTICALS, INC. 00228 ACTAVIS ELIZABETH LLC 62559 ANIP ACQUISITION COMPANY 45963 ACTAVIS INC. 54436 ANTARES PHARMA, INC. 46987 ACTAVIS KADIAN LLC 52609 APO-PHARMA USA, INC. 49687 ACTAVIS KADIAN LLC 60505 APOTEX CORP. 14550 ACTAVIS PHARMA MFGING PRIVATE LIMITED 63323 APP PHARMACEUTICALS, LLC. 67767 ACTAVIS SOUTH ATLANTIC 42865 APTALIS PHARMA US, INC 66215 ACTELION PHARMACEUTICALS U.S., INC. 58914 APTALIS PHARMA US, INC. 52244 ACTIENT PHARMACEUTICALS 13310 AR SCIENTIFIC, INC. 75989 ACTON PHARMACEUTICALS 08221 ARBOR PHARM IRELAND LIMITED 76431 AEGERION PHARMACEUTICALS, INC. 60631 ARBOR PHARMACEUTICALS IRELAND LIMITED 50102 AFAXYS, INC. 24338 ARBOR PHARMACEUTICALS, INC. 10572 AFFORDABLE PHARMACEUTICALS, LLC 59923 AREVA PHARMACEUTICALS 27241 AJANTA PHARMA LIMITED 76189 ARIAD PHARMACEUTICALS, INC. 17478 AKORN INC 24486 ARISTOS PHARMACEUTICALS, INC. 24090 AKRIMAX PHARMACEUTICALS LLC 67877 ASCEND LABORATORIES, L.L.C. 68220 ALAVEN PHARMACEUTICAL, LLC 76388 ASPEN GLOBAL INC. 00065 ALCON LABORATORIES, INC. 51248 ASTELLAS 00998 ALCON LABORATORIES, INC. 00469 ASTELLAS PHARMA US, INC. 25682 ALEXION PHARMACEUTICALS 00186 ASTRAZENECA LP 68611 ALIMERA SCIENCES, INC.
  • Promotion and Development Collaborations Between Established Players

    Promotion and Development Collaborations Between Established Players

    Promotion and Development Collaborations Between Established Players Randall B. Sunberg Pharma and Biotech In-Licensing, Co-Development and Co-Promotion Agreements October 21-22, 2002 1 www.morganlewis.com MorganMorgan Lewis:Lewis: LifeLife SciencesSciences FocusFocus • Founded in 1873, today 1,100 lawyers in 13 offices worldwide • 175 Life Sciences professionals, including 90 with advanced degrees ranging from biochemistry to molecular genetics to immunology • Interdisciplinary coordination of transactions, IP, litigation, FDA and antitrust expertise to meet our clients’ strategic objectives • Recently ranked as the 5th leading transactional law firm in the nation by The American Lawyer "Corporate Scorecard” • Named by many Fortune 250 companies as one of their primary law firms • Recognized by corporate counsel for exceptional client service in a survey of Fortune 1000 companies • Featured prominently in the annual National Law Journal survey of “Who Defends Corporate America” 2 MorganMorgan Lewis:Lewis: RecentRecent LifeLife SciencesSciences DealsDeals • Aventis - Genta collaboration for co-development and commercialization of Genasense™ • Enzon - Elan acquisition of Abelcet® product rights and manufacturing assets • Quintiles - Eli Lilly co-promotion and marketing collaboration for Cymbalta™ • Adolor - GlaxoSmithKline development and commercialization collaboration for Alvimopan™ • Arena Pharmaceuticals - Merck drug discovery collaboration • Cephalon - Anesta stock-for-stock public company acquisition • Aventis - Millennium alliance
  • Galena Biopharma, Inc. (Exact Name of Registrant As Specified in Its Charter) ______

    Galena Biopharma, Inc. (Exact Name of Registrant As Specified in Its Charter) ______

    ANNUAL REPORT 201 OUR MISSION GALENA BIOPHARMA DEVELOPS AND COMMERCIALIZES INNOVATIVE, TARGETED ONCOLOGY TREATMENTS THAT ADDRESS MAJOR UNMET MEDICAL NEEDS TO ADVANCE CANCER CARE. MANAGEMENT TEAM Mark J. Ahn, Ph.D., President & Chief Executive Officer Remy Bernarda, Vice President, Marketing & Communications Gavin Choy, Pharm.D., Senior Vice President, Clinical Operations & Cinical Science Ryan Dunlap, CPA, Vice President, Chief Financial Officer Brian Hamilton, M.D., Ph.D., Executive Vice President & Chief Medical Officer Robert Laliberte, MS, Vice President, Clinical Operations & Clinical Science Christopher Lento, Vice President, Sales & Commercial Operations Hana B. Moran, Ph.D., Senior Vice President, Regulatory & Compliance Patricia Murphy, Vice President, Regulatory Affairs & Compliance Mark W. Schwartz, Ph.D., Executive Vice President & Chief Operating Officer SCIENTIFIC ADVISORY BOARD COL George Peoples, M.D., F.A.C.S., Chief, Surgical Oncology, Brooke Army Medical Center; Director and Principal Investigator, Cancer Vaccine Development Program, San Antonio Military Medical Center Hope S. Rugo, M.D., Clinical Professor of Medicine, Division of Hematology and Oncology at the University of California San Francisco Helen Diller Family Comprehensive Cancer Care Center Robert Figlin, M.D., F.A.C.P., Dr. Figlin is a fellow of the American College of Physicians and the International Society for Biologic Therapy as well as a member of the American Society of Clinical Oncology, the American Association for Cancer Research, and the American Urological Association. Dr. Gabriel N. Hortobagyi, M.D., F.A.C.P., is a Professor of Medicine and Chairman of the Department of Breast Medical Oncology and holds the Nellie B. Connally Chair in Breast Cancer Research at the University of Texas MD Anderson Cancer Center (MDACC).
  • Biotech Watchlist 2013 Update: Exciting Ideas Have Explosive Potential

    Biotech Watchlist 2013 Update: Exciting Ideas Have Explosive Potential

    Biotech Watchlist 2013 Update: Exciting Ideas Have Explosive Potential The Life Sciences Report www.TheLifeSciencesReport.com 05/02/2013 In January 2013, The Life Sciences Report debuted its biotech COMPANIES MENTIONED Watchlist, which outlined ideas for investors keyed to catalysts in Amarin Corp. the drug development process that typically move biotechnology Astellas Pharma Inc. stocks. All stocks are affected by catalysts, but nowhere do they Bayer provide more leverage (or deleverage) than in biotech. We Cardinal Health Inc. predicted the new year would present legitimate prospects for Celsion Corp. portfolio growth. So far, that has been the case. Although the party has given Galena Biopharma Inc. way to some fatigue, the punch bowl is still on the table and the biotech Hyperion Therapeutics upswing continues. Inc. Medivation Inc. Source: George S. Mack of The Life Sciences Report Navidea Biopharmaceuticals Inc. Back in January, our friends and collaborators at San Diego-based Sagient Novartis AG Research, publishers of the BioMedTracker, offered important information about Onyx Pharmaceuticals market-moving data and events that can make or break smaller companies. In Inc. addition, a group of key biotech analysts weighed in on their best ideas—17 stocks Peregrine Pharmaceuticals Inc. in all. It was the perfect storm of individual ideas combined with a biotech wind from Pfizer Inc. 2012 still billowing the sails. As of April 22, the NASDAQ Biotechnology (NBI) Pharmacyclics Inc. index is up 26.6%. Have the biotech companies that made inaugural Biotech Prana Biotechnology Ltd. Watchlist—and their stocks—met the targets identified in the first quarter of 2013? Sangamo BioSciences Are there new catalysts? Check out the progress in the updated April 2013 Biotech Inc.
  • 11/09/2016 Provider Subsystem Healthcare and Family Services Run Time: 20:25:21 Report Id 2794D051 Page: 01

    11/09/2016 Provider Subsystem Healthcare and Family Services Run Time: 20:25:21 Report Id 2794D051 Page: 01

    MEDICAID SYSTEM (MMIS) ILLINOIS DEPARTMENT OF RUN DATE: 11/09/2016 PROVIDER SUBSYSTEM HEALTHCARE AND FAMILY SERVICES RUN TIME: 20:25:21 REPORT ID 2794D051 PAGE: 01 NUMERIC COMPLETE LIST OF PHARMACEUTICAL LABELERS WITH SIGNED REBATE AGREEMENTS IN EFFECT AS OF 01/01/2017 NDC NDC PREFIX LABELER NAME PREFIX LABELER NAME 00002 ELI LILLY AND COMPANY 00145 STIEFEL LABORATORIES, INC, 00003 E.R. SQUIBB & SONS, LLC. 00149 WARNER CHILCOTT PHARMACEUTICALS INC. 00004 HOFFMANN-LA ROCHE 00168 E FOUGERA AND CO. 00006 MERCK & CO., INC. 00169 NOVO NORDISK, INC. 00007 GLAXOSMITHKLINE 00172 IVAX PHARMACEUTICALS, INC. 00008 WYETH LABORATORIES 00173 GLAXOSMITHKLINE 00009 PFIZER, INC 00178 MISSION PHARMACAL COMPANY 00013 PFIZER, INC. 00182 GOLDLINE LABORATORIES, INC. 00015 MEAD JOHNSON AND COMPANY 00185 EON LABS, INC. 00023 ALLERGAN INC 00186 ASTRAZENECA LP 00024 SANOFI-AVENTIS, US LLC 00187 VALEANT PHARMACEUTICALS NORTH AMERICA 00025 PFIZER, INC. 00206 LEDERLE PIPERACILLIN 00026 BAYER HEALTHCARE LLC 00224 KONSYL PHARMACEUTICALS, INC. 00029 GLAXOSMITHKLINE 00225 B. F. ASCHER AND COMPANY, INC. 00032 SOLVAY PHARMACEUTICALS, INC. 00228 ACTAVIS ELIZABETH LLC 00037 MEDA PHARMACEUTICALS, INC. 00245 UPSHER-SMITH LABORATORIES, INC. 00039 SANOFI-AVENTIS, US LLC 00258 FOREST LABORATORIES INC 00046 AYERST LABORATORIES 00259 MERZ PHARMACEUTICALS 00049 PFIZER, INC 00264 B. BRAUN MEDICAL INC. 00051 UNIMED PHARMACEUTICALS, INC 00281 SAVAGE LABORATORIES 00052 ORGANON USA INC. 00299 GALDERMA LABORATORIES, L.P. 00053 CSL BEHRING 00300 TAP PHARMACEUTICALS INC 00054 ROXANE LABORATORIES, INC. 00310 ASTRAZENECA LP 00056 BRISTOL-MYERS SQUIBB PHARMA CO. 00327 GUARDIAN LABS DIV UNITED-GUARDIAN INC 00062 ORTHO MCNEIL PHARMACEUTICALS 00338 BAXTER HEALTHCARE CORPORATION 00064 HEALTHPOINT, LTD. 00378 MYLAN PHARMACEUTICALS, INC.
  • The Bottom 99

    The Bottom 99

    The Top 100 June 1, 2004 A list of stocks topping our custom 'torpedo’ screen. Updated monthly. ABFI AMER BUSINESS FINL SVCS INC Financials ABGX ABGENIX INC Health Care ADLR ADOLOR CORP Health Care AGEN ANTIGENICS INC/DEL Health Care AGI ALLIANCE GAMING CORP Consumer Cyclicals AKLM ACCLAIM ENMNT INC Technology ALKS ALKERMES INC Health Care ALXN ALEXION PHARMACEUTICALS INC Health Care AMLN AMYLIN PHARMACEUTICALS INC Health Care APHT APHTON CORP Health Care ARNA ARENA PHARMACEUTICALS INC Health Care BIOV BIOVERIS CORP Health Care BMRN BIOMARIN PHARMACEUTICAL INC Health Care BVSN BROADVISION INC Technology CBRX COLUMBIA LABORATORIES INC Health Care CCRD CONCORD COMMUNICATIONS INC Technology CDE COEUR D'ALENE MINES CORP Basic Materials CFFN CAPITOL FEDERAL FINANCIAL Financials COMS 3COM CORP Technology CPN CALPINE CORP Utilities CRAY CRAY INC Technology CRGN CURAGEN CORP Health Care CRXA CORIXA CORP Health Care CYBX CYBERONICS INC Health Care DAL DELTA AIR LINES INC Capital Goods DEPO DEPOMED INC Health Care DMX I-TRAX INC Health Care DRXR DREXLER TECHNOLOGY CORP Technology DSCO DISCOVERY LABORATORIES INC Health Care DV DEVRY INC Capital Goods ELGX ENDOLOGIX INC Health Care EPIX EPIX MEDICAL INC Health Care EXEL EXELIXIS INC Health Care EXLT EXULT INC Capital Goods FCP FALCON PRODUCTS INC Capital Goods FMKT FREEMARKETS INC Technology FXEN FX ENERGY INC Energy GBTVK GRANITE BROADCASTING Consumer Cyclicals GENE OSCIENT PHARMACEUTICALS CORP Health Care GGNS GENUS INC Technology GLFD GUILFORD PHARMACEUTICAL INC Health Care GMRK GULFMARK OFFSHORE
  • Pierre Cremieux October 2020 CV (English)

    Pierre Cremieux October 2020 CV (English)

    PIERRE-YVES CREMIEUX, PH.D. President Office: 617 425 8135 111 Huntington Avenue Fax: 617 425 8001 14th Floor [email protected] Boston, MA 02199 Pierre-Yves Cremieux, President of Analysis Group, has a broad range of expertise in health economics, antitrust, statistics, and labor economics. He has consulted to numerous clients in the United States and Canada and testified in bench and jury trials, arbitrations, and administrative proceedings. Dr. Cremieux has served as an expert and supported other experts in both litigation and non-litigation matters on antitrust issues; general commercial claims; contractual disputes; and a number of labor- related matters in a variety of industries, including high tech, pharmaceuticals, biotech, financial products, consumer products, and commodities. He has assessed the evaluation of damages on a class-wide basis in some of the largest class action matters in recent years. His scientific research in antitrust economics, class certification, health economics, and statistics has been published in numerous peer-reviewed journals, including the George Mason Law Review, the American Bar Association Economics Committee Newsletter, The Review of Economics and Statistics, the Journal of Health Economics, Industrial and Labor Relations Review, the Journal of Clinical Oncology, and The American Journal of Managed Care. Dr. Cremieux’s research has been cited in leading media outlets including The Wall Street Journal and Forbes. Dr. Cremieux has frequently presented at leading legal, health care, and economics seminars on topics such as antitrust, class certification, health economics, and statistics, in both the United States and Canada. He has also been invited to teach courses on economics, statistics, health care, and antitrust at various schools including McGill University, Boston University, Harvard Medical School, and the Yale School of Management.